Updated on 2026/03/31

写真a

 
Tsuchiya Atsunori
 
Organization
Graduate Faculty of Interdisciplinary Research Faculty of Medicine Clinical Medicine (Respiratory Medicine) Professor
Title
Professor
External link

Name(s) appearing in print

  • Atsunori Tsuchiya

Research History

  • 山梨大学医学部消化器内科 教授

    2024.11

    　 More details

  • 新潟大学大学院医歯学総合研究科消化器内科学分野 准教授

    2021.9 - 2024.10

    　 More details

Current state of research and teaching activities

  • BCC実習
    ACC実習

Research Areas

  • Life Science / Gastroenterology

  • Life Science / General internal medicine

  • Life Science / Gastroenterology

Research Interests

  • 細胞外小胞

  • 膵癌

  • 再生医療

  • 肝細胞癌

  • Major achievement
    肝硬変

  • 肝線維化

  • 肝再生

  • 癌幹細胞

  • 生活習慣病

  • 消化器内科

  • 再生医療

  • エクソソーム

Subject of research

  • 消化器内科全般、肝細胞癌、肝硬変、肝再生、

Proposed theme of joint or funded research

  • 消化器全般、再生医療

    　More details

    Possible form of cooperation：Cooperative Research Type of joint or funded research proposed：Wish to undertake joint research with industry and other organizations including private sector.

Research Projects

  • 消化器疾患におけるPS-PLA1（Phosphatidylserine-specific Phospholipase A1）の役割についての検討  Major achievement

    2025.8

    東ソー株式会社 

    　 More details

    Grant type：Collaborative (industry/university)  Type of fund：：Joint research

  • 早期膵癌診断マーカーの同定と診断キット開発を⽬的とした 膵液の網羅的蛋⽩・糖鎖解析  Major achievement

    2025.7 - 2028.3

    RCMG 

    　 More details

    Grant type：Collaborative (industry/university)  Type of fund：：Joint research

  • B 型肝炎患者におけるHBsAgGi と各種血中HBV マーカーとの関連および臨床的有用性の検討  Major achievement

    2025.4

    　 More details

    Grant type：Collaborative (industry/university)  Type of fund：：Joint research

  • 抗炎症性マクロファージをターゲットとする細胞外小胞の開発とPOCの確立を目指した新規抗線維化療法の開発

    2025.4 - 2028.3

    日本医療研究開発機構  肝炎等克服実用化研究事業 

    　 More details

    Authorship：Coinvestigator(s) 

  • 非代償期を含むC型肝硬変患者のインターフェロンフリーDAA治療後の長期アウトカムを明らかにする研究

    2025.4 - 2028.3

    日本医療研究開発機構  肝炎等克服実用化研究事業 

  • １分子ロングリードシークエンス技術によるHBV全遺伝子解析と病態解明

    2025.4 - 2028.3

    日本医療研究開発機構  肝炎等克服実用化研究事業 

    　 More details

    Authorship：Coinvestigator(s)  Grant type：Competitive 

  • AIとオミックス情報の融合によるC型肝炎ウイルス排除後における線維化進展および肝発癌予測モデルの構築

    2025.4 - 2028.3

    日本医療研究開発機構  肝炎等克服実用化研究事業 

    　 More details

    Authorship：Coinvestigator(s)  Grant type：Competitive 

  • 細菌由来の細胞外小胞を活用したがんリスク診断・予防法の開発  Major achievement

    2025.4 - 2028.3

    日本医療研究開発機構  革新的がん医療実用化研究事業 

    　 More details

    Authorship：Coinvestigator(s)  Grant type：Competitive  Type of fund：：Others

  • Extracellular Vesicles Regulate Progressive Congestive Hepatopathy due to Heart Failure

    Grant number：23K07372  2023.4 - 2026.3

    Japan Society for the Promotion of Science  Niigata University  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    　 More details

  • Elucidation of the Mechanism of Regenerative Insufficiency in Advanced Liver Cirrhosis Caused by Intestinal Bacterial Extracellular Vesicles and Development of Prevention and Treatment Methods

    Grant number：23K24128  2022.4 - 2025.3

    Japan Society for the Promotion of Science  Niigata University  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    　 More details

  • 非アルコール性脂肪肝炎の病態を制御する肝臓由来の悪玉細胞外小胞の同定と治療法開発

    Grant number：22551408  2022.4 - 2025.3

    文部科学省  科学研究費助成事業 基盤研究（Ｂ） 

    寺井崇二, 土屋淳紀

    　 More details

    Authorship：Coinvestigator(s) 

    researchmap

  • Identification of malignant extracellular vesicles of liver origin that regulate nonalcoholic steatohepatitis and the development of the treatment

    Grant number：22H03055  2022.4 - 2025.3

    Japan Society for the Promotion of Science  Niigata University  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    　 More details

  • Identification of malignant extracellular vesicles of liver origin that regulate nonalcoholic steatohepatitis and the development of the treatment

    Grant number：23K24316  2022.4 - 2025.3

    Japan Society for the Promotion of Science  Niigata University  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    　 More details

  • Pancreatic cancer biomarker research by the exosome proteome analysis of the HGD rat pancreatic cancer model

    Grant number：21K07910  2021.4 - 2024.3

    Japan Society for the Promotion of Science  Niigata University  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    　 More details

  • ADR-001を用いたChild-Pugh Aの肝硬変患者を対象とした医師主導治験

    Grant number：20314294  2021.4 - 2024.3

    国立研究開発法人日本医療研究開発機構  日本医療研究開発機構研究費 

    寺井崇二、土屋淳紀、小野寺理、渡邉雄介

    　 More details

  • Development of a treatment to improve fibrosis and elucidation of carcinogenesis mechanisms in improved NASH model MC4RKO mice

    Grant number：19H03636  2019.4 - 2022.3

    Japan Society for the Promotion of Science  Niigata University  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    Terai Shuji

    　 More details

    Using MC4R-KO mice, a mouse model of NASH, we first examined the effects on fibrosis and tumors to establish an early fibrosis model and an early tumorigenesis model. Using the early fibrosis model, we found that mesenchymal stem cells and their exosomes ameliorate inflammation and fibrosis. Furthermore, in the tumorigenesis model, we established an early tumorigenesis model by blocking S1P-S1PR2 signaling in MC4R-KO mice fed a high-fat diet with the drug JTE-013, and found that the mice showed a high rate of hepatocellular carcinoma at early stage.

    researchmap

  • Aiming for the improvement of regenerative ability of the liver from hepatic stem cells by analyzing the role of SDF-1

    Grant number：20790488  2008 - 2009

    Japan Society for the Promotion of Science  Niigata University  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)  Grant-in-Aid for Young Scientists (B)

    TSUCHIYA Ataunori

    　 More details

    In the liver, stromal cell derived factor-1 (SDF-1) is produced in the bile duct and hepatic stem/progenitor cells. In this study, we analyzed the role of SDF-1 by using the CXCR4 conditional knock out (KO) mice (CXCR4 is the receptor of SDF-1). By analyzing the liver damaged CXCR4 KO mice, we realized that although in the liver hepatic stem/progenitor cells increased, the recovery of liver regeneration was delayed. These results reveal that the role of SDF-1/CXCR4 axis works positive effect for liver regeneration.

    researchmap

▼display all

Papers

  • Mesenchymal stromal cell administration promotes macrophage-mediated bile duct regeneration.

    Regen Ther   2026.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Post-to Pretreatment Ratio of Serum CXCL10 Level Predicts Short-Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct-Acting Antiviral Therapy. Reviewed

    Suzuki T, Matsuura K, Tahata Y, Hikita H, Enomoto M, Tsuchiya A, Miki D, Yatsuhashi H, Kuroda H, Yamashita T, Yoshiji H, Tamaki N, Mawatari S, Miyaaki H, Asahina Y, Hiasa Y, Uchida Y, Nakamoto Y, Takami T, Kodama T, Takehara T.

    Hepatol Res   2026.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Significance of Measuring Interferon-γ-Induced Protein-10 Levels in Patients Receiving Systemic Therapies for Unresectable Hepatocellular Carcinoma. Reviewed

    akada H, Osawa L, Komiyama Y, Muraoka M, Suzuki Y, Sato M, Kobayashi S, Yoshida T, Takano S, Maekawa S, Tsuchiya A, Enomoto N.

    Oncology   2026.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination. Reviewed

    Myojin Y, Hikita H, Tahata Y, Fukumoto K, Kato S, Sasaki Y, Kumazaki S, Tsuchiya A, Enomoto M, Miki D, Yatsuhashi H, Kuroda H, Uchida Y, Yoshiji H, Yamashita T, Mawatari S, Tamaki N, Miyaaki H, Asahina Y, Suda G, Matsuura K, Nakamoto Y, Hiasa Y, Takami T, Shirai K, Maesaka K, Murai K, Makino Y, Saito Y, Kodama T, Tatsumi T, Takehara T.

    2026.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma. Invited Reviewed

    Yuichiro Suzuki, Teiji Kuzuya, Leona Osawa, Yasuyuki Komiyama, Hitomi Takada, Shuya Matsuda, Masaru Muraoka, Mitsuaki Sato, Shinya Maekawa, Nobuyuki Enomoto, Hisanori Muto, Yoshihiko Tachi, Yoshiki Hirooka, Atsunori Tsuchiya

    Hepatology research : the official journal of the Japan Society of Hepatology   55 ( 12 )   1675 - 1682   2025.12

    　More details

    Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Atezolizumab plus bevacizumab (AB) is a standard first-line therapy for unresectable hepatocellular carcinoma (HCC). However, data on the efficacy and safety of AB rechallenge (re-AB) after discontinuation are limited. METHODS: We conducted a retrospective analysis of 13 patients with unresectable HCC who received initial AB treatment and re-AB at the University of Yamanashi and Fujita Health University. Rechallenge was defined as reinitiating AB after prior discontinuation followed by one or more other systemic therapies. Tumor responses were assessed using RECIST v1.1 and modified RECIST (mRECIST), and adverse events (AEs) were evaluated according to CTCAE v5.0. RESULTS: During initial AB, the objective response rate (ORR), disease control rate (DCR), and median progression-free survival (mPFS) were 15%, 69%, and 3.7 months, respectively. AB was discontinued due to disease progression or immune-related AEs. Re-AB was administered after a median of two intervening regimens. In the re-AB phase, ORR, DCR, and mPFS were 15%, 54%, and 4.7 months, respectively. Despite prior progression, two patients achieved partial response and five had stable disease. No worsening of previously observed AEs occurred during re-AB. CONCLUSIONS: AB rechallenge may be a safe and potentially effective treatment option for selected patients with unresectable HCC, even after discontinuation due to disease progression or adverse events.

    DOI： 10.1111/hepr.70024

    PubMed

    researchmap

  • Regulatory T cell stability determines the efficiency of bile duct regeneration during cholangitis. Invited Reviewed

    Naruhiro Kimura, Man Chun Wong, Ben Higgins, Gareth Hardisty, Pei-Chi Huang, Matamoana Muller, Maxym Besh, Daniel A Patten, Timothy Kendall, Prakash Ramachandran, Adriano G Rossi, Graham Anderson, Shishir Shetty, David Withers, Atsunori Tsuchiya, Shuji Terai, Wei-Yu Lu

    Cell reports   44 ( 11 )   116557 - 116557   2025.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Cholangiopathies such as primary sclerosing cholangitis (PSC) cause damage to the bile ducts with no effective cure. Reduction and impairment in the function of regulatory T cells (Tregs) occur in PSC. We investigate whether Tregs regulate bile duct regeneration and the dynamics of Treg turnover during bile duct injury. We use the transgenic Foxp3GFPDTR model to mimic reduced Treg infiltration in PSC and show that Tregs mediate cholangiocyte response to biliary injury. Fate mapping of Tregs reveals that intrahepatic Tregs acquire a pro-inflammatory phenotype, even after interleukin-2 (IL-2)-mediated Treg expansion. Ox40L expression correlates with fibrosis in PSC patients. Enhancing Treg numbers through IL-2 complex administration and blocking Ox40 signaling simultaneously suppresses the inflammatory phenotype of Tregs and reduces bile duct damage and fibrosis. We demonstrate that bile duct regeneration can be enhanced by combining Treg-based therapy and targeting co-stimulatory molecules, such as Ox40L.

    DOI： 10.1016/j.celrep.2025.116557

    PubMed

    researchmap

  • Bradycardic Responses During Thermal Ablation for Hepatocellular Carcinoma: Impact of Procedural Pain Severity and Autonomic Imbalance. Invited Reviewed

    Yasuyuki Komiyama, Masaru Muraoka, Tetsuya Iijima, Leona Osawa, Hitomi Takada, Yuichiro Suzuki, Mitsuaki Sato, Shinichi Takano, Shinya Maekawa, Atsunori Tsuchiya, Nobuyuki Enomoto

    Hepatology research : the official journal of the Japan Society of Hepatology   55 ( 11 )   1518 - 1530   2025.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    AIM: Bradycardic responses frequently occur during radiofrequency ablation (RFA) and microwave ablation (MWA) for hepatocellular carcinoma (HCC), but the impact of procedural pain severity and patient-specific factors remains unclear. This study aimed to evaluate the incidence and risk factors for bradycardic responses, focusing on procedural pain and autonomic regulation. METHODS: This retrospective study included 267 patients with solitary HCC who underwent RFA or MWA between 2019 and 2024. Bradycardic responses were defined as a ≥ 30% decrease in heart rate from baseline or < 50 bpm. Patients were categorized by procedural pain severity using patient-controlled analgesia (PCA) bolus administration. Risk factors for bradycardia were assessed by logistic regression. RESULTS: Bradycardic responses occurred in 70 patients (26.2%). Severe procedural pain (odds ratio [OR], 2.26 and p = 0.007) and primary HCC (OR, 2.68 and p = 0.002) were independent risk factors. In patients without severe pain, absence of angiotensin II receptor blocker (ARB) use increased bradycardia risk (OR, 0.14 and p = 0.013). Most bradycardic events (61.4%) occurred within 3 min of ablation initiation. CONCLUSIONS: Bradycardic responses during RFA and MWA are common and linked to procedural pain severity and autonomic imbalance. Comprehensive management, including pain control, medication review, and addressing procedural anxiety through counseling or sedation, may reduce risks and enhance procedural safety.

    DOI： 10.1111/hepr.70013

    PubMed

    researchmap

  • 重度肝障害と血球貪食症候群発症を併発した自己免疫性膵炎・胆管炎の1例 Invited Reviewed

    古屋 圭一, 山下 洸司, 奥脇 徹也, 吉村 大, 倉富 夏彦, 川上 智, 高野 伸一, 土屋 淳紀

    日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集   77回・99回   57 - 消   2025.11

    　More details

    Language：Japanese   Publisher：日本消化器病学会-甲信越支部  

    researchmap

  • 膵炎および膵液瘻の原因精査および治療に工夫を要した1例 Invited Reviewed

    加藤 圭悟, 吉村 大, 高野 伸一, 川上 智, 倉富 夏彦, 奥脇 徹也, 山下 洸司, 土屋 淳紀

    日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集   77回・99回   研専1 - 研   2025.11

    　More details

    Language：Japanese   Publisher：日本消化器病学会-甲信越支部  

    researchmap

  • 消化器病学×デジタル革新:AIとSNSが拓く新時代 当科の診療、教育におけるSNS活用の現状 Invited Reviewed

    大澤 玲於奈, 吉田 貴史, 土屋 淳紀

    日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集   77回・99回   S - 消   2025.11

    　More details

    Language：Japanese   Publisher：日本消化器病学会-甲信越支部  

    researchmap

  • 持続する発熱を契機として診断と治療に至った免疫関連有害事象の3例 Invited Reviewed

    柚木 亮汰, 村岡 優, 大澤 玲於奈, 松田 秀哉, 鈴木 雄一朗, 佐藤 光明, 前川 伸哉, 土屋 淳紀

    日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集   77回・99回   31 - 研   2025.11

    　More details

    Language：Japanese   Publisher：日本消化器病学会-甲信越支部  

    researchmap

  • 原因・薬物治療と側副血行路遮断にてrecompensationし、大腸癌手術が行えた肝硬変の一例 Invited Reviewed

    齊藤 咲紀, 村岡 優, 穐山 みなみ, 大澤 玲於奈, 松田 秀哉, 鈴木 雄一朗, 佐藤 光明, 山本 瀬里, 安村 智生, 雨宮 史武, 高野 伸一, 前川 伸哉, 佐々木 優, 岡田 大樹, 荒木 拓次, 古屋 信二, 市川 新太郎, 近藤 哲夫, 市川 大輔, 土屋 淳紀

    日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集   77回・99回   29 - 専   2025.11

    　More details

    Language：Japanese   Publisher：日本消化器病学会-甲信越支部  

    researchmap

  • 「消化器領域の魅力を伝えるために-消化器への勧誘と教育の工夫-」 山梨大学消化器内科の臨床実習 Invited Reviewed

    鈴木 雄一朗, 倉富 夏彦, 松田 秀哉, 村岡 優, 久野 徹, 川上 智, 佐藤 光明, 吉田 貴史, 小林 祥司, 高野 伸一, 前川 伸哉, 土屋 淳紀

    日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集   77回・99回   W2 - 消   2025.11

    　More details

    Language：Japanese   Publisher：日本消化器病学会-甲信越支部  

    researchmap

  • 「消化器疾患処置におけるリスクマネージメント-合併症、高齢者への対策-」 炎症の局在からみるERCP後膵炎の検討 Invited Reviewed

    山下 洸司, 高野 伸一, 奥脇 徹也, 吉村 大, 倉富 夏彦, 川上 智, 土屋 淳紀

    日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集   77回・99回   W1 - 消   2025.11

    　More details

    Language：Japanese   Publisher：日本消化器病学会-甲信越支部  

    researchmap

  • 肝硬変の形成メカニズムに着目した線維化改善・再生医療の可能性 Invited Reviewed Major achievement

    土屋淳紀

    肝臓   2025.10

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)  

  • 偶発症を軽減する安全なEUS-HGSの工夫 Invited Reviewed

    倉富 夏彦, 高野 伸一, 山下 洸司, 奥脇 徹也, 今川 直人, 吉村 大, 川上 智, 土屋 淳紀

    Gastroenterological Endoscopy   67 ( Suppl.2 )   2174 - 2174   2025.10( ISSN：0387-1207  eISSN：1884-5738 )

    　More details

    Language：Japanese   Publisher：(一社)日本消化器内視鏡学会  

    researchmap

  • 膵管アプローチをした際に発症するERCP後膵炎の機序解明 Invited Reviewed

    山下 洸司, 高野 伸一, 奥脇 徹也, 今川 直人, 吉村 大, 倉富 夏彦, 川上 智, 土屋 淳紀

    Gastroenterological Endoscopy   67 ( Suppl.2 )   2179 - 2179   2025.10( ISSN：0387-1207  eISSN：1884-5738 )

    　More details

    Language：Japanese   Publisher：(一社)日本消化器内視鏡学会  

    researchmap

  • 学会におけるキャリア形成を振り返って(良い点,課題など) Invited Reviewed

    土屋 淳紀

    日本消化器がん検診学会雑誌   63 ( Suppl大会 )   840 - 840   2025.10( ISSN：1880-7666  eISSN：2185-1190 )

    　More details

    Language：Japanese   Publisher：(一社)日本消化器がん検診学会  

    researchmap

  • 学会におけるキャリア形成を振り返って 良い点,課題など Invited Reviewed

    土屋 淳紀

    Gastroenterological Endoscopy   67 ( Suppl.2 )   1918 - 1918   2025.10( ISSN：0387-1207  eISSN：1884-5738 )

    　More details

    Language：Japanese   Publisher：(一社)日本消化器内視鏡学会  

    researchmap

  • Risk Factors for the Exacerbation of Esophageal Varices in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma. Invited Reviewed

    Hitomi Takada, Leona Osawa, Yasuyuki Komiyama, Masaru Muraoka, Yuichiro Suzuki, Mitsuaki Sato, Shoji Kobayashi, Takashi Yoshida, Shinichi Takano, Shinya Maekawa, Atsunori Tsuchiya, Nobuyuki Enomoto

    Oncology   1 - 14   2025.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: Atezolizumab plus bevacizumab (AB) therapy is an effective systemic therapy for unresectable hepatocellular carcinoma (u-HCC). However, exacerbations of esophageal varices (EV) often occur, and EV management should be clarified to attain a better prognosis in patients with u-HCC. Our research aimed to explore the actual situation of EV exacerbation and its risk factors in patients receiving AB therapy. METHODS: We recruited 82 patients receiving AB therapy for u-HCC. All patients underwent esophagogastroduodenoscopy (EGD) within 3 months before AB induction to assess EV presence. The emergence of EV findings requiring urgent or planned endoscopic treatment defined EV exacerbation. The frequency and risk factors for EV exacerbation after AB introduction were analyzed. RESULTS: Of the participants, 49% had EV findings on preinduction EGD. Within the observation period, 17% had EV exacerbation, and 7.2% experienced rupture. Among those with EV exacerbation, 7 had positive red color signs, and 1 had formal deterioration to F3. In EV rupture, 4 had eruptive hemorrhage, 1 had gushing hemorrhage, and 1 had a white plug. Independent factors requiring therapeutic intervention for EV exacerbation were EV treatment history, drug-resistant ascites effusion, esophageal intramural vessel (EIV) diameter >3.3 mm, and left gastric vein (LGV) diameter >4.9 mm on computed tomography (CT) scan. CONCLUSION: Patients with EV treatment history, drug-resistant ascites effusion, and EIV and LGV diameters >3.3 and 4.9 mm via CT, respectively, may require careful monitoring for possible EV exacerbation, enabling better EV management, adequate AB therapy, and finally, prolonged patient survival.

    DOI： 10.1159/000548667

    PubMed

    researchmap

  • Zinc Acetate Inhibits Hepatitis A Virus Replication: Possible Treatment for Patients with Type A Acute-on-Chronic Liver Failure. Reviewed

    Kanda T, Sasaki-Tanaka R, Abe H, Yokoo T, Sakamaki A, Hayashi K, Kamimura H, Tsuchiya A, Masuzaki R, Kogure H, Okamoto H, Terai S.

    Pathogens   2025.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Risk Factors for the Exacerbation of Esophageal Varices in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma. Reviewed

    Takada H, Osawa L, Komiyama Y, Muraoka M, Suzuki Y, Sato M, Kobayashi S, Yoshida T, Takano S, Maekawa S, Tsuchiya A, Enomoto N.

    Oncology   2025.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • 肝アブレーションの徐脈発作における疼痛とリスク因子の検討 Invited Reviewed

    小宮山泰之, 村岡優, 大澤玲於奈, 高田ひとみ, 鈴木雄一朗, 佐藤光明, 前川伸哉, 榎本信幸, 土屋淳紀

    肝臓   66 ( Supplement 2 )   A631 - A631   2025.9( ISSN：0451-4203  eISSN：1881-3593 )

    　More details

    Language：Japanese   Publisher：(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • 学会におけるキャリア形成を振り返って(良い点,課題など) Invited Reviewed

    土屋淳紀

    肝臓   66 ( Supplement 2 )   A500 - A500   2025.9( ISSN：0451-4203  eISSN：1881-3593 )

    　More details

    Language：Japanese   Publisher：(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • 再生誘導医療の開発 肝臓に対する再生誘導医療 Invited Reviewed

    土屋 淳紀

    臨床神経学   65 ( Suppl. )   S95 - S95   2025.9( ISSN：0009-918X  eISSN：1882-0654 )

    　More details

    Language：Japanese   Publisher：(一社)日本神経学会  

    researchmap

  • HCVマイクロ・エリミネーションへの試み~山梨県における取り組み~ Invited Reviewed

    前川伸哉, 井上泰輔, 土屋淳紀

    肝臓   66 ( Supplement 2 )   A571 - A571   2025.9( ISSN：0451-4203  eISSN：1881-3593 )

    　More details

    Language：Japanese   Publisher：(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • Revisiting Hepatic Fibrosis Risk in Congenital Heart Disease: Insights from Non-Invasive Markers and Echocardiography.

    Yamazaki F, Kamimura H, Endo S, Miida S, Maruyama H, Yoshida T, Kumagai M, Kimura N, Abe H, Sakamaki A, Yokoo T, Tsukada M, Numano F, Saitoh A, Watanabe M, Shiraishi S, Tsuchida M, Fujiki S, Kashimura T, Inomata T, Nonaka H, Kamimura K, Tsuchiya A, Terai S.

    Children   2025.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Narrative Review. Reviewed

    Kanda T, Sasaki-Tanaka R, Abe H, Kimura N, Yoshida T, Hayashi K, Sakamaki A, Yokoo T, Kamimura H, Tsuchiya A, Kamimura K, Terai S.

    Int J Mol Sci.   2025.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Multidirectional therapeutic effects of synthesized HMGB1 peptide on liver cirrhosis in mice. Reviewed Major achievement

    2025.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Cholestasis in hepatitis E virus infection.

    Kanda T, Sasaki-Tanaka R, Yokoo T, Hayashi K, Kamimura H, Tsuchiya A, Terai S.

    World J Hepatol.   2025.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Guidance on the clinical application of extracellular vesicles. Reviewed Major achievement

    Terai S, Asonuma M, Hoshino A, Kino-Oka M, Ochiya T, Okada K, Sato Y, Takahashi Y, Tobita M, Tsuchiya A.

    Regen Ther. 2025 Mar 7;29:43-50. doi: 10.1016/j.reth.2025.02.008. PMID: 40124467; PMCID: PMC11930518.   2025.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Targeted animal models for preclinical assessment of cellular and gene therapies in pancreatic and liver diseases: regulatory and practical insights.

    Wang H, Ciccocioppo R, Terai S, Shoeibi S, Carnevale G, De Marchi G, Tsuchiya A, Ishii S, Tonouchi T, Furuyama K, Yang Y, Mito M, Abe H, Di Tinco R, Cardinale V.

    Cytotherapy. 2025 Mar;27(3):259-278. doi: 10.1016/j.jcyt.2024.11.008. Epub 2024 Nov 19. PMID: 39755978.   2025.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Targeted animal models for preclinical assessment of cellular and gene therapies in pancreatic and liver diseases: regulatory and practical insights. Invited Reviewed

    Hongjun Wang, Rachele Ciccocioppo, Shuji Terai, Sara Shoeibi, Gianluca Carnevale, Giulia De Marchi, Atsunori Tsuchiya, Soichi Ishii, Takafumi Tonouchi, Kaito Furuyama, Yuan Yang, Masaki Mito, Hiroyuki Abe, Rosanna Di Tinco, Vincenzo Cardinale

    Cytotherapy   27 ( 3 )   259 - 278   2025.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Cellular and gene therapy (CGT) products have emerged as a popular approach in regenerative medicine, showing promise in treating various pancreatic and liver diseases in numerous clinical trials. Before these therapies can be tested in human clinical trials, it is essential to evaluate their safety and efficacy in relevant animal models. Such preclinical testing is often required to obtain regulatory approval for investigational new drugs. However, there is a lack of detailed guidance on selecting appropriate animal models for CGT therapies targeting specific pancreatic and liver conditions, such as pancreatitis and chronic liver diseases. In this review, the gastrointestinal committee for the International Society for Cell and Gene Therapy provides a summary of current recommendations for animal species and disease model selection, as outlined by the US Food and Drug Administration, with references to EU EMA and Japan PMDA. We discuss a range of small and large animal models, as well as humanized models, that are suitable for preclinical testing of CGT products aimed at treating pancreatic and liver diseases. For each model, we cover the associated pathophysiology, commonly used metrics for assessing disease status, the pros and limitations of the models, and the relevance of these models to human conditions. We also summarize the use and application of humanized mouse and other animal models in evaluating the safety and efficacy of CGT products. This review aims to provide comprehensive guidance for selecting appropriate animal species and models to help bridge the gap between the preclinical research and clinical trials using CGT therapies for specific pancreatic and liver diseases.

    DOI： 10.1016/j.jcyt.2024.11.008

    PubMed

    researchmap

  • Human placental extract improves liver cirrhosis in mice with regulation of macrophages and senescent cells.

    Ishikawa N, Watanabe Y, Maeda Y, Yoshida T, Kimura N, Abe H, Sakamaki A, Kamimura H, Yokoo T, Kamimura K, Tsuchiya A, Terai S.

    Regen Ther. 2025 Feb 4;28:509-516. doi: 10.1016/j.reth.2025.01.017. PMID: 39991509; PMCID: PMC11846928.   2025.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Pruritus in Chronic Cholestatic Liver Diseases, Especially in Primary Biliary Cholangitis: A Narrative Review.

    Kanda T, Sasaki-Tanaka R, Kimura N, Abe H, Yoshida T, Hayashi K, Sakamaki A, Yokoo T, Kamimura H, Tsuchiya A, Kamimura K, Terai S.

    Int J Mol Sci. 2025 Feb 22;26(5):1883. doi: 10.3390/ijms26051883. PMID: 40076514; PMCID: PMC11900276.   2025.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Small Intestinal Bacterial Overgrowth Is a Predictor of Overt Hepatic Encephalopathy in Patients with Liver Cirrhosis.

    Sakamaki A, Yokoyama K, Yamazaki H, Wakabayashi T, Kojima Y, Tominaga K, Tsuchiya A, Kamimura K, Yokoyama J, Terai S.

    J Clin Med. 2025 Feb 23;14(5):1491. doi: 10.3390/jcm14051491. PMID: 40094949; PMCID: PMC11901010.   2025.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • 高齢者表在型食道扁平上皮癌に対するESD非治癒切除例の追加治療と予後の検討 Invited Reviewed

    久野徹, 小林祥司, 大高雅彦, 大高雅彦, 石田剛士, 吉田貴史, 土屋淳紀

    日本食道学会学術集会抄録集(CD-ROM)   79th   2025

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 食道癌化学療法の薬剤選択基準と治療成績 Invited Reviewed

    小林祥司, 大高雅彦, 依田宏貴, 青沼優子, 石田剛士, 久野徹, 吉田貴史, 山口達也, 榎本信幸, 土屋淳紀

    日本消化器病学会甲信越支部例会抄録集   76th   2025

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 膵癌早期診断でのSPACE施行に付加する膵液CEA同時測定の有用性 Invited Reviewed

    奥脇徹也, 高野伸一, 川上智, 倉富夏彦, 吉村大, 今川直人, 山下洸司, 土屋淳紀

    日本消化器病学会雑誌(Web)   122   2025( ISSN：1349-7693 )

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 胆管癌切除断端の良悪性判別を目的とした経口胆道鏡(POCS)画像の人工知能ディープラーニング解析 Invited Reviewed

    山下洸司, 深澤佳満, 深澤佳満, 高野伸一, 奥脇徹也, 吉村大, 倉富夏彦, 川上智, 土屋淳紀

    胆道(Web)   39 ( 3 )   2025( ISSN：1883-6879 )

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 経皮的ドレナージとinterventional EUSで改善した気腫性膵炎の1例 Invited Reviewed

    山下洸司, 川上智, 今川直人, 奥脇徹也, 吉村大, 倉富夏彦, 高野伸一, 土屋淳紀

    日本消化器病学会甲信越支部例会抄録集   76th   2025

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 慢性肝臓病(CLD)から肝硬変,肝臓癌まで~新たな話題を中心に~ Invited Reviewed

    土屋淳紀

    日本消化器病学会甲信越支部例会抄録集   76th   2025

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 当院におけるHCC化学療法の実際 Invited Reviewed

    鈴木雄一朗, 大澤玲於奈, 村岡優, 佐藤光明, 前川伸哉, 榎本信幸, 土屋淳紀

    日本消化器病学会甲信越支部例会抄録集   76th   2025

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 偶発症を軽減する安全なEUS-HGSの工夫 Invited Reviewed

    倉富夏彦, 高野伸一, 山下洸司, 奥脇徹也, 今川直人, 吉村大, 川上智, 土屋淳紀

    Gastroenterological Endoscopy (Web)   67 ( Supplement2 )   2025( ISSN：1884-5738 )

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • バセドウ病を合併したE型肝炎の1例 Invited Reviewed

    穐山みなみ, 大澤玲於奈, 村岡優, 鈴木雄一朗, 佐藤光明, 前川伸哉, 土屋淳紀

    日本消化器病学会甲信越支部例会抄録集   76th   2025

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • Two cases of severe alcoholic hepatitis with different outcomes after steroid treatment Invited Reviewed

    村岡優, 大澤玲於奈, 土屋淳紀

    アルコールと医学生物学   44   2025

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • Kasabach-Merritt症候群を合併する巨大肝血管腫の一例 Invited Reviewed

    飯沼南帆, 大澤玲於奈, 村岡優, 鈴木雄一朗, 佐藤光明, 前川伸哉, 土屋淳紀, 雨宮秀武

    日本消化器病学会甲信越支部例会抄録集   76th   2025

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • IBD診療における病診連携の検討 Invited Reviewed

    久野徹, 岩本史光, 依田宏貴, 青沼優子, 石田剛士, 小林祥司, 吉田貴史, 土屋淳紀

    日本消化器病学会雑誌(Web)   122   2025( ISSN：1349-7693 )

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • Platelet-rich plasma-derived extracellular vesicles improve liver cirrhosis in mice.

    Maeda Y, Watanabe Y, Ishikawa N, Yoshida T, Kimura N, Abe H, Sakamaki A, Kamimura H, Yokoo T, Kamimura K, Tsuchiya A, Terai S.

    Regen Ther. 2024 Nov 6;26:1048-1057. doi: 10.1016/j.reth.2024.10.010. PMID: 39569343; PMCID: PMC11576940.   2024.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • 難治性の肝・胆道疾患に関する調査研究 ACLFに対する老化細胞除去剤の効果機序解析 Invited Reviewed

    寺井崇二, 土屋淳紀, 渡邉雄介

    難治性の肝・胆道疾患に関する調査研究 令和5年度 総括・分担研究報告書(Web)   2024

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

▼display all

Books and Other Publications

  • 非代償性肝硬変 Major achievement

    土屋淳紀（ Role： Single Work）

    2026.1 

    　More details

    Language：Japanese   Book type：Scholarly book

  • 肝性脳症

    土屋淳紀

    2026.1 

    　More details

    Language：Japanese  

  • 肝硬変診療・治療の最新動向

    2025.11 

    　More details

    Language：Japanese  

  • 肝線維化・肝硬変の進展

    2025.7 

    　More details

    Language：Japanese  

  • 肝硬変診療ガイドライン改訂に向けて

    2025.7 

    　More details

    Language：Japanese  

Presentations

  • Liver fibrosis improvement and regeneration induction therapy for cirrhosis Major achievement

    2025.11 

    　More details

    Language：English   Presentation type：Symposium workshop panel(nominated)  

  • 肝疾患のEV研究

    土屋淳紀

    第12回日本細胞外小胞学会学術集会  2025.10 

    　More details

    Language：Japanese  

  • 肝硬変マネジメントの最新情報 Invited Major achievement

    土屋淳紀

    2025年度日本肝臓学会前期教育講演会  2025.6  日本肝臓学会

    　More details

    Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

  • 肝臓に対する再生誘導療法

    土屋淳紀

    第66回日本神経学会学術集会  2025.5 

    　More details

    Language：Japanese  

  • 細胞外小胞等の臨床応用に関するガイダンスの作成に関わって

    土屋淳紀

    第24回日本再生医療学会総会  2025.3 

    　More details

    Language：Japanese   Presentation type：Symposium workshop panel(nominated)  

    Venue：横浜  

The total number of announcement other than the above

  • 2025

    Total number of non-preannounced events：15  Number of main presenters：15  Number of presenters other than main person：0

Industrial Property Rights

  • 血中アンモニアを低下させる剤

    寺井 崇二, 土屋 淳紀, 吉田智彰, 門田 吉弘, 栃尾 巧, 高橋 志達, 岡 健太郎

    　More details

    Application no：特願2020-185985 

    researchmap

  • 肝線維化疾患の予防又は治療剤

    寺井 崇二, 土屋 淳紀, 小島 雄一, 山下 潤二, 原 幸生, 中島 謙治

    　More details

    Application no：特願PCT/JP2018/034709 

    researchmap

  • 筋肉量率の増加剤、水分量率の増加剤および体脂肪率の減少剤

    寺井 崇二, 土屋 淳紀, 冨永 顕太郎, 門田 吉弘, 栃尾 巧, 高橋 志達, 岡 健太郎, 峯村 菜花

    　More details

    Application no：特願2020-120744 

    researchmap

  • 発明の名称：脂肪肝および非アルコール性脂肪肝炎の治療薬

    寺井 崇二, 土屋 淳紀, 玉井 克人, 新保 敬史, 山﨑 尊人

    　More details

    Application no：PCT/JP2021/36238 

    researchmap

  • マクロファージの誘導方法、抗炎症性マクロファージの誘導剤及び医薬組成物

    寺井 崇二, 土屋 淳紀, 竹内 卓

    　More details

    Application no：PCT/JP2020/9639 

    researchmap

Awards

  • Liver forum in Kyoto研究奨励賞

    2007  

    　More details

Teaching Experience (On-campus)

  • Gastroenterology （Basic Clinical Clerkship） Major achievement

    2025Year

  • Advanced Clinical Science I (Internal Medicine)

    2025Year

  • Hepatology and viral hepatitis Seminar Major achievement

    2025Year

  • Hepatology and viral hepatitis Experiment Major achievement

    2025Year

  • Advanced Course of Liver Patho logy

    2025Year

  • Gastroenterology （Basic Clinical Clerkship） Major achievement

    2024Year

  • Internal Medicine 1 (Basic Clinical Clerkship) Major achievement

    2024Year

  • ACC実習 Major achievement

    2024Year

▼display all

Guidance results

  • 2025

    Type：Ph.D. dissertations guidance

    Number of people receiving guidance ：1people 

Other undergraduate student guidance

  • 2025

    Guidance to life and extracurricular activities - total time：10hours

Other educational achievements

  • 第二回　国家試験対策勉強会

    2025

  • 第一回　国家試験対策勉強会

    2025

Textbooks and teaching materials

  • 消化器内科　症例集

     2025.04

  • 消化器内科　ワンポイント解説集

     2025.04

Review of master's and doctoral thesis

  • 2025

    Examiner classification：Second reader

    Master ：1people  (Overseas student)：1people

    Doctoral ：0people  (Overseas student)：0people

    Thesis Dr. ：1people  (Overseas student)：1people

Social Activities

  • 消化器内科で知っていただきたいこと ～肝臓を中心に～

    Role(s)： Lecturer

    山梨大学  2025.11

  • 消化器内科で知っていただきたいこと ～長寿の方を診療してきての健康アドバイス～ Major achievement

    Role(s)： Lecturer

    都留市  2025.10

  • 命を支える消化器内科： 臨床から研究まで

    Role(s)： Lecturer

    山梨大学  山梨県下高校生への公開授業  2025.7

  • 肝がん撲滅運動 市民公開講座講師

    Role(s)： Lecturer

    2016

    　More details

  • BSNラジオ近藤丈靖の独占ごきげんアワーでの肝炎啓発活動

    Role(s)： Appearance

    　More details

  • アルビレックス新潟の試合での肝炎啓発活動

    Role(s)： Appearance,　Planner

    　More details

  • 身体障害者福祉法15条指定医

    　More details

  • 肝臓病教室 講師

    Role(s)： Lecturer,　Planner

    　More details

  • 肝炎コーディネーター養成講座講師

    Role(s)： Lecturer,　Planner

    　More details

  • 新潟市での肝炎無料検査活動

    Role(s)： Planner,　Demonstrator

    　More details

  • 新潟大学医学部準硬式野球部監督

    　More details

  • 新潟大学オープンキャンパス 高校生エコー実演

    Role(s)： Lecturer

    　More details

  • 佐渡市における市民公開講座

    Role(s)： Lecturer,　Planner

    　More details

▼display all

Professional Memberships

  • European Association for Study of Liver

    2026.1 - 2026.12

    　 More details

  • 日本細胞外小胞学会

    2025.4 - 2026.3

  • 日本消化器病学会

    2025.4 - 2026.3

  • 日本肝臓学会

    2025.4 - 2026.3

  • 日本消化器内視鏡学会

    2025.4 - 2026.3

  • 日本再生医療学会

    2025.4 - 2026.3

  • 日本内科学会

    2025.4 - 2026.3

  • 日本内科学会；認定医・専門医・指導医

    2025.4 - 2026.3

    　 More details

  • International Society of Extracellular Vesicles (ISEV；国際細胞外小胞学会)

    2025.4 - 2025.12

    　 More details

  • 日本炎症・再生医学会

    　 More details

  • 日本消化器病学会；専門医・指導医・甲信越支部評議員・本部評議員

    　 More details

  • 日本消化器内視鏡学会 専門医 指導医 甲信越評議員

    　 More details

  • 日本消化器免疫学会

    　 More details

  • 日本再生医療学会；認定医・代議員・幹事

    　 More details

  • 日本細胞外小胞学会

    　 More details

  • 日本食品免疫学会

    　 More details

  • 日本肝臓学会；専門医・指導医・東部会評議員・評議員

    　 More details

▼display all

Committee Memberships

  • 日本消化器病学会・日本肝臓学会   肝硬変診療ガイドライン作成委員長   Major achievement

    2025.4 - 2028.3   

    　 More details

    Committee type：Society

  • 日本再生医療学会   理事長補佐  

    2025.4 - 2026.3   

    　 More details

    Committee type：Society

  • 日本再生医療学会   エクソソームの調整・治療に対する考え方ワーキンググループメンバー  

       

    　 More details

  • 日本再生医療学会   細胞外小胞等の臨床応用に関するガイドライン策定ワーキンググループ  

       

    　 More details

  •   次世代医療機器・再生医療等製品評価指標作成事業再生医療審査ワーキンググループ委員  

       

    　 More details

  •   日本肝臓学会；東部会評議員・評議員  

       

    　 More details

  •   日本肝臓学会 肝移植委員会ホームページ作成ワーキンググループ委員  

       

    　 More details

  •   日本肝臓学会 欧文紙Hepatology Research Associated Editor  

       

    　 More details

  •   日本肝臓学会 再生医療レジストリ協議会議員  

       

    　 More details

  •   日本肝臓学会 award 選考委員  

       

    　 More details

  •   日本消化器病学会；甲信越支部評議員・本部評議員  

       

    　 More details

  •   日本消化器病学会 再生医療推進委員会委員  

       

    　 More details

  •   日本消化器内視鏡学会；甲信越支部評議員  

       

    　 More details

  •   日本再生医療学会；代議員・幹事  

       

    　 More details

  •   日本再生医療学会 再生医療認定医制度委員会委員  

       

    　 More details

  •   日本再生医療学会 再生医療認定医ワーキンググループオブザーバー  

       

    　 More details

  •   日本再生医療学会 COI委員会書記  

       

    　 More details

  •   日本内科学会 専門医部会信越支部運営委員  

       

    　 More details

▼display all